INMiND: getting to the bottom of neuroinflammation.
Dara
D
Mohammadi
D000544:Alzheimer Disease / Q000209:etiology / Q000517:prevention & control; D000682:Amyloid / Q000378:metabolism; D000818:Animals; D001315:Australia; D015415:Biomarkers / Q000032:analysis; D001812:Blood-Brain Barrier; D060825:Cognitive Dysfunction / Q000188:drug therapy; D003299:Cooperative Behavior; D042241:Early Diagnosis; D000068800:Etanercept; D005060:Europe; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology*; D007391:International Cooperation; D017628:Microglia / Q000737:chemistry / Q000502:physiology*; D019636:Neurodegenerative Diseases / Q000209:etiology / Q000473:pathology* / Q000517:prevention & control / Q000628:therapy; D059906:Neuroimaging / Q000191:economics; D009474:Neurons / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D000682:Amyloid; D015415:Biomarkers; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept